Saturday, 11 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Here’s What to Expect From Johnson & Johnson’s Next Earnings Report
Economy

Here’s What to Expect From Johnson & Johnson’s Next Earnings Report

Last updated: June 28, 2025 4:00 am
Share
Here’s What to Expect From Johnson & Johnson’s Next Earnings Report
SHARE

Johnson & Johnson (JNJ) is a leading healthcare company headquartered in New Brunswick, New Jersey. The company is known for its research and development, manufacturing, and sale of various healthcare products worldwide. With a market capitalization of $366.4 billion, Johnson & Johnson operates through its Innovative Medicine and MedTech segments.

The company is gearing up to announce its second-quarter results on Wednesday, July 16. Analysts are projecting a non-GAAP earnings of $2.65 per share, a 6% decrease from the previous year. Despite the anticipated decline, Johnson & Johnson has consistently exceeded analysts’ expectations in recent quarters. For the full fiscal year 2025, earnings are expected to reach $10.60 per share, representing a 6.2% increase from the previous year. In fiscal 2026, earnings are projected to rise by 3.6% year-over-year to $10.98 per share.

Over the past 52 weeks, JNJ stock has shown a 3.5% growth, outperforming the Health Care Select Sector SPDR Fund’s 8.1% decline but falling short of the S&P 500 Index’s 12.1% increase during the same period. Despite delivering better-than-expected financial results in the first quarter, Johnson & Johnson’s stock experienced a slight dip initially. However, the company’s solid growth in US sales led to a 2.4% year-over-year increase in overall revenue to $21.9 billion. Additionally, adjusted earnings per share rose by 2.2% to $2.77, exceeding consensus estimates.

Analysts have a cautiously optimistic outlook on JNJ, with a “Moderate Buy” rating overall. Of the 23 analysts covering the stock, nine rate it as a “Strong Buy,” two as a “Moderate Buy,” and 12 as a “Hold.” The mean price target of $169.14 suggests an 11.3% upside potential from the current price levels.

See also  Klarna produces more startups than any other European fintech: Accel

In conclusion, Johnson & Johnson continues to demonstrate resilience and growth in the healthcare industry. Investors are eagerly awaiting the company’s upcoming earnings report to gain further insights into its financial performance and future outlook. This article was originally published on Barchart.com and is intended for informational purposes only.

TAGGED:EarningsExpectHeresJohnsonJohnsonsreport
Share This Article
Twitter Email Copy Link Print
Previous Article Creating Bird Flu Vaccines for Humans at a Biosecure Laboratory Creating Bird Flu Vaccines for Humans at a Biosecure Laboratory
Next Article Summer 2025 Hot Shots … June Gloom?! More Like June Bloom! Summer 2025 Hot Shots … June Gloom?! More Like June Bloom!
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Can Trump really defund public schools that recognize transgender students?

Los Angeles public schools have implemented policies that provide transgender students with equal access to…

October 28, 2024

‘The View’ Scores Best Premiere Ratings in Five Years (EXCLUSIVE)

This season, viewers are spending more time engaging with “The View.” The daytime talk show…

September 25, 2025

Next-Gen Sealant Speeds Recovery After Retinal Surgery, Study Finds

Retinal Detachment is a serious condition that can result in permanent vision loss if not…

May 6, 2025

SEND spend could hit £15bn without reform, warns IFS

The IFS urges the fiscal watchdog to release yearly projections for high-needs funding and potential…

October 2, 2025

New PGG Wrightson store up and running

Exciting news for agricultural company PGG Wrightson - their brand new store and office is…

August 5, 2025

You Might Also Like

Nebius Group (NBIS) Jumps 8.7% on AI Buying Spree
Economy

Nebius Group (NBIS) Jumps 8.7% on AI Buying Spree

October 11, 2025
Report: Illegal Immigrants Collected  BILLION in Medicaid Payments | The Gateway Pundit | by Gregory Lyakhov
Politics

Report: Illegal Immigrants Collected $7 BILLION in Medicaid Payments | The Gateway Pundit | by Gregory Lyakhov

October 11, 2025
Coinbase, Mastercard Eye Billion Dollar Deals for Stablecoin Firm BVNK: Report
Economy

Coinbase, Mastercard Eye Billion Dollar Deals for Stablecoin Firm BVNK: Report

October 11, 2025
General Mills (GIS) Remains One of the Most Reliable Food Dividend Stocks for Steady income
Economy

General Mills (GIS) Remains One of the Most Reliable Food Dividend Stocks for Steady income

October 11, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?